DiRocco Derek — SEC Form 4 filings
SEC reporting owner CIK 1792061. 11 Form 4 filings on record with FilingPulse; latest filed 2026-06-22.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-02-05 to 2026-06-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| 89bio, Inc. (ETNB) | Director | 3 | — | — | 9 |
| Acrivon Therapeutics, Inc. (ACRV) | Director | 4 | — | — | 4 |
| Mineralys Therapeutics, Inc. (MLYS) | Director | 3 | — | — | 4 |
| Werewolf Therapeutics, Inc. (HOWL) | Director | 1 | — | — | 1 |
Form 4 filings — DiRocco Derek
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-22 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-02-20 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Grant/award (A): 6,200 @ $0 · Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2025-10-30 | 4 | 89bio, Inc. (ETNB) | Disposition to issuer (D): 7,000 (derivative) @ $0 · Disposition to issuer (D): 7,000 (derivative) @ $0 · Disposition to issuer (D): 12,500 (derivative) @ $0 · Disposition to issuer (D): 25,000 (derivative) @ $0 · Disposition to issuer (D): 27,400 (derivative) @ $0 · Disposition to issuer (D): 45,150 (derivative) @ $0 · +1 more | EDGAR |
| 2025-06-17 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Grant/award (A): 32,900 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 56,400 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Werewolf Therapeutics, Inc. (HOWL) | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 45,150 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1792061 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →